Mario Menéndez Conde

Language: Spanish
References: 14
Page: 107-108
PDF size: 49.83 Kb.

Text Extraction

No Abstract

REFERENCES

1. Huff D. How to he with statistics. W.W. Norton & Company, 2nd Ed. 1982: 1.

2. Kaplan NM. La decisión para utilizar fármacos. En: Kaplan NM. Tratamiento de la hipertensión. 7a Ed. DF. México EMIS, Inc. Medical Publishers 1998: 62-69.

3. Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.

4. Wyse DG, Waldo AL, Di Marco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.

5. Ridker PM, Guldhaber SZ, Danielson E et al. Long term, low intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.

6. Menéndez-Conde M. Medicina basada en evidencias. Reducción relativa vs reducción absoluta de riesgo. Rev Mex Cardiol 2003; 14: 57-60.

7. Huff D, op. cit. p.74.

8. Ridker PM, Cannon CP, Morrow D et al. C reactive protein levels and outcomes after satin therapy. N Engl J Med 2005; 352: 20-28.

9. Huff D, op. cit., p.19.

10. Topol EJ. Editorial. A sea change in cardiovascular prevention. N Engl J Med 2004; 350: 1562-64.

11. Avorn J. Torcetrapib and atorvastatin. Should marketing drive the research agenda? N Engl J Med 2005; 352: 2573-76.

12. Fischer MA, Avorn J. Economic implications of evidence-based prescribing for hypertension: can better care cost less? JAMA 2004; 291: 1850-56.

13. Menéndez-Conde M. Carta al Editor. Rev Mex Cardiol 2003; 14: 26-27.

14. Menéndez-Conde. Carta al Editor. Rev Mex Cardiol 2005; 16: 48-49.